Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Blood (2025) 146 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2025-LBA-6

Published: 2025

Journal Articles

Incidence and risk factors for infections in the real-world setting in newly diagnosed myeloma patients treated with modern induction regimens

Efstathios Kastritis, Eirini Solia, Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Despina Fotiou, Stavroula Giannouli, Panagiotis Tsirigotis, Maria Gavriatopoulou, Evangelos Terpos, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 2228.

https://doi.org/10.1182/blood-2025-2228

Published: 2025

Journal Articles

Burden and characteristics of infections in patients treated with bispecific antibodies and the impact of immunoglobulin replacement

Efstathios Kastritis, Eirini Solia, Ilias Katsadouros, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 2227.

https://doi.org/10.1182/blood-2025-2227

Published: 2025

Journal Articles

Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival

Panagiotis Malandrakis, Ioannis Kostopoulos, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Sotirios Manganas, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Vasiliki Spiliopoulou, Magdalini Migkou, Despina Fotiou, Foteini Theodorakakou, Efstathios Kastritis, Maria Gavriatopoulou, Ourania Tsitsilonis, Meletios Dimopoulos, Evangelos Terpos

Blood (2025) 146 (Supplement 1): 2216.

https://doi.org/10.1182/blood-2025-2216

Published: 2025

Journal Articles

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies

Blood (2025) 146 (Supplement 1): 403.

https://doi.org/10.1182/blood-2025-403

Published: 2025

Journal Articles

Von willebrand factor levels show independent prognostic significance in patients with AL amyloidosis treated with daratumumab-based therapies

Foteini Theodorakakou, Zoey Kapsimali, Alexandra Papadimou, Katerina Chrisostomidou, Kostantina Taouxi, Ilias Katsadouros, Panagiotis Malandrakis, Magdalini Migkou, Eirini Solia, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Evangelos Eleutherakis Papaiakovou, Asimina Papanikolaou, Maria Gavriatopoulou, Evangelos Terpos, Eleni Pergantou, Meletios Dimopoulos, Ioannis Papassotiriou, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 2192.

https://doi.org/10.1182/blood-2025-2192

Published: 2025

Journal Articles

Characteristics and clinical course of younger Patients with early lesions in a contemporary cohort of 1240 patients: Low risk features and low risk of complications

Eirini Solia, Foteini Theodorakakou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Konstantinos Giannakas, Stavroula Giannouli, Panagiotis Tsirigotis, Asimina Papanikolaou, Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Dimopoulos, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 2191.

https://doi.org/10.1182/blood-2025-2191

Published: 2025

Journal Articles

Management and long-term hematologic and neurologic outcomes of IgM-related neuropathy: A single center experience

Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Sotirios Manganas, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Eirini Solia, Evangelos Eleutherakis-Papaiakovou, Ilias Katsadouros, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Terpos, Efstathios Kastritis, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 2184.

https://doi.org/10.1182/blood-2025-2184

Published: 2025

Journal Articles

Characterization of the plasma proteome of multiple myeloma and its precursor conditions and identification of a prognostic high-risk signature of progression

Blood (2025) 146 (Supplement 1): 2168.

https://doi.org/10.1182/blood-2025-2168

Published: 2025

Journal Articles

Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström's Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström's Macroglobulinemia (ECWM)

Blood (2025) 146 (Supplement 1): 223.

https://doi.org/10.1182/blood-2025-223

Published: 2025

Journal Articles

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Blood (2025) 146 (Supplement 1): 5812.

https://doi.org/10.1182/blood-2025-5812

Published: 2025

Journal Articles

Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients

Efstathios Kastritis, Maria Gavriatopoulou, Foteini Theodorakakou, Eirini Solia, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Stavroula Giannouli, Panagiotis Tsirigotis, Asimina Papanikolaou, Despina Fotiou, Konstantinos Giannakas, Erasmia Boutakoglou, Evangelos Terpos, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 923.

https://doi.org/10.1182/blood-2025-923

Published: 2025

Journal Articles

A comparison between subcutaneous isa-vrd from the isasocut study and intravenous isa-vrd from the imroz study in patients with transplant- ineligible newly diagnosed multiple myeloma

Arthur Bobin, Mohamad Mohty, Philippe Moreau, Hartmut Goldschmidt, Meletios Dimopoulos, Robert Orlowski, Cyrille Touzeau, Aurore Perrot, Thomas Chalopin, Mamoun Dib, Lydia Montes, Umer Khan, Mony Morisse, Rick Zhang, Corina Oprea, Florence Suzan Teisserenc, Thierry Facon, Xavier Leleu

Blood (2025) 146 (Supplement 1): 7566.

https://doi.org/10.1182/blood-2025-7566

Published: 2025

Journal Articles

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression

Jonathan Kaufman, Efstathios Kastritis, Nisha Joseph, Maria Gavriatopoulou, Lilly Gu, Craig Hofmeister, Vikas Gupta, Evangelos Terpos, Ajay Nooka, Sagar Lonial, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 407.

https://doi.org/10.1182/blood-2025-407

Published: 2025

Journal Articles

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Blood (2025) 146 (Supplement 1): 494.

https://doi.org/10.1182/blood-2025-494

Published: 2025

Journal Articles

MagnetisMM-6 part 2: A phase 3, open-label, randomized study of elranatamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma

Ja Min Byun, Meletios Dimopoulos, Eeman Shaikh, Karen Gogat-Marchant, Nina N. Green, Domenico Cieri, Hang Quach

Blood (2025) 146 (Supplement 1): 5845.

https://doi.org/10.1182/blood-2025-5845

Published: 2025

Journal Articles

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change

Suzanne Trudel, Vania Hungria, María-Victoria Mateos, Chee Paul Lin, Julie Byrne, James Parker, Molly Purser, Sandhya Sapra, Farrah Pompilus, Sumita Roy-Ghanta, Giulia Fulci, Joanna Opalinska, Neal Sule, Brandon Kremer, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 5823.

https://doi.org/10.1182/blood-2025-5823

Published: 2025

Journal Articles

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Blood (2025) 146 (Supplement 1): 5820.

https://doi.org/10.1182/blood-2025-5820

Published: 2025

Journal Articles

Safety and efficacy of linvoseltamab (LINVO) combined with anti-CD38 monoclonal antibodies (mAbs) daratumumab (DARA) or isatuximab (ISA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the multicohort, Phase 1b LINKER-MM2 trial

Meletios Dimopoulos, Sosana Delimpasi, Salomon Manier, Jean-Marie Michot, Enrique Ocio, Samuel Rubinstein, Joselle Cook, Maria Del Carmen Martinez Chamorro, Aurora Breazna, Amishi Dhadwal, Yogita Ghodke, Sheila Masinde, Glenn Kroog, Shawn Sarkaria, Albert Oriol

Blood (2025) 146 (Supplement 1): 2254.

https://doi.org/10.1182/blood-2025-2254

Published: 2025

Journal Articles

The novel ims / IMWG high-risk multiple myeloma criteria may omit individuals with renal impairment and adverse disease prognosis

Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Eirini Solia, Evangelos Eleutherakis-Papaiakovou, Ilias Katsadouros, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Erasmia Boutakoglou, Konstantinos Giannakas, Evangelos Terpos, Meletios Dimopoulos, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 3986.

https://doi.org/10.1182/blood-2025-3986

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Incidence and risk factors for infections in the real-world setting in newly diagnosed myeloma patients treated with modern induction regimens

Burden and characteristics of infections in patients treated with bispecific antibodies and the impact of immunoglobulin replacement

Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies

Von willebrand factor levels show independent prognostic significance in patients with AL amyloidosis treated with daratumumab-based therapies

Characteristics and clinical course of younger Patients with early lesions in a contemporary cohort of 1240 patients: Low risk features and low risk of complications

Management and long-term hematologic and neurologic outcomes of IgM-related neuropathy: A single center experience

Characterization of the plasma proteome of multiple myeloma and its precursor conditions and identification of a prognostic high-risk signature of progression

Dexamethasone, Rituximab and Cyclophosphamide with Bortezomib is a rapidly acting and highly efficient first-line treatment in Waldenström's Macroglobulinemia: Final analysis of ECWM-1 trial of the European Consortium for Waldenström's Macroglobulinemia (ECWM)

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients

A comparison between subcutaneous isa-vrd from the isasocut study and intravenous isa-vrd from the imroz study in patients with transplant- ineligible newly diagnosed multiple myeloma

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

MagnetisMM-6 part 2: A phase 3, open-label, randomized study of elranatamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Safety and efficacy of linvoseltamab (LINVO) combined with anti-CD38 monoclonal antibodies (mAbs) daratumumab (DARA) or isatuximab (ISA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the multicohort, Phase 1b LINKER-MM2 trial

The novel ims / IMWG high-risk multiple myeloma criteria may omit individuals with renal impairment and adverse disease prognosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only